ABSTRACT
Nasopharyngeal carcinoma (NPC) is distinct from other cancers of the head and neck in biology, epidemiology, histology, natural history, and response to treatment. Radiation therapy is an essential component of curative-intent of non-disseminated disease and the association of chemotherapy improves the rates of survival. In the case of metastatic disease stages, treatment requires platinum/gemcitabine-based chemotherapy and patients may achieve a long survival time (AU)
No disponible
Subject(s)
Humans , Nasopharyngeal Neoplasms/therapy , Carcinoma, Squamous Cell/therapy , Practice Guidelines as Topic , Neoplasm Metastasis/therapy , Neoplasm Recurrence, Local/therapy , Risk FactorsABSTRACT
Head and neck cancer represents 5 % of oncologic cases in adults. Early stage treatments are local with surgery and/or radiotherapy. For locally advanced stages, treatment requires radiotherapy combined with platinum-based drugs or cetuximab. Induction chemotherapy should be considered for selected cases. In the case of metastatic disease, adjuvant or palliative treatment is based on platinum agents and cetuximab (AU)
Subject(s)
Humans , Adult , Head and Neck Neoplasms/therapy , Algorithms , Antibodies, Monoclonal, Humanized/administration & dosage , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Drug Administration Schedule , Head and Neck Neoplasms/diagnosis , Head and Neck Neoplasms/pathology , Neoplasm Metastasis , Neoplasm StagingABSTRACT
Nasopharyngeal carcinoma cases are not frequently encountered in our environment. Local stages are treated with radiotherapy. For advanced local stages, the association of chemotherapy with radiotherapy improves the rates of survival. In the case of metastatic disease stages, treatment requires platinum-based chemotherapy and patients may achieve a long survival time (AU)
